
Collegium Pharmaceutical (COLL) Stock Forecast & Price Target
Collegium Pharmaceutical (COLL) Analyst Ratings
Bulls say
Collegium Pharmaceutical Inc. is experiencing a positive trajectory in its financial performance, highlighted by a significant 19% year-over-year revenue growth for Jornay PM, which reached $42 million, surpassing market expectations. The product has gained a noteworthy market share of 23.4%, up from approximately 17% in the previous quarter, with a robust script growth driven by increased prescriptions among both pediatric and adult patients. With the ongoing enhancements in gross-to-net (GTN) improvements and the expansion of its sales force, Collegium is poised for sustained growth, particularly with Jornay PM serving as a key driver in the coming years.
Bears say
Collegium Pharmaceutical Inc. is facing a negative outlook due to projected declines in sales for critical products, including Xtampza ER and Belbuca, which are anticipated to contribute approximately $620 million in revenue by 2026, representing a year-over-year decrease. The company also faces significant risks from potential generic competition affecting its pain portfolio, coupled with higher-than-expected expenditures that could hinder profitability. Additionally, uncertain commercialization prospects, including potential delays, quality issues from third-party suppliers, and unfavorable pricing dynamics, further exacerbate the challenges to achieving its financial targets.
This aggregate rating is based on analysts' research of Collegium Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.
Collegium Pharmaceutical (COLL) Analyst Forecast & Price Prediction
Start investing in Collegium Pharmaceutical (COLL)
Order type
Buy in
Order amount
Est. shares
0 shares